October 14 2020

Beacon Pharmaceuticals Limited (BPL) has launched Pandovir 100, a broad-spectrum antiviral medicine, for the treatment of severe Covid-19 cases under the generic of Remdesivir.

July 29 2020

Beacon is delighted after launching Multiple Tyrosine Kinase Inhibitor (TKI), Pazonix that is only for the treatment of renal cell carcinoma

July 29 2020

Beacon Medicare Limited launches Pembroxim for the treatment of Cancer Immunotherapy

July 29 2020

Beacon Medicare Limited has launched Blockbuster drug Nivolunix for Non Small Cell Lung Cancer patients.

July 29 2020

Megahit Product Nilonix has successfully launched by Beacon for the treatment of Philadelphia chromosome-positive CML for export purpose.

December 09 2019

Beacon proudly introduces highly potent multi-targeted third generation BCR-ABL Tyrosine Kinase Inhibitor Ponatinib which is the only treatment indicated for the adult patients with T315I+ CML or T315I+ Ph+ ALL or where no other TKI is indicated.

July 03 2019

Blockbuster product "Hernix" has successfully launched by Beacon for Early stage HER2 Breast Cancer patients

July 03 2019

Beacon introduced another block buster drugs Cabozanitib

July 03 2019

Beacon Medicare Ltd. introduced another block buster drugs Obetix for Cirrhosis Treatment

July 01 2019

New lung cancer drug introduces by Beacon.

July 01 2019

Beacon introduces another new drug for Breast Cancer treatment.

July 01 2019

New drug launched by Beacon for Rheumatic arthritis.

July 01 2019

BEACON introduces yet another blockbuster anticancer drug, Lenvatinib